

**FORWARDHEALTH
PRIOR AUTHORIZATION / PREFERRED DRUG LIST (PA/PDL)
FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), INCLUDING
CYCLO-OXYGENASE INHIBITORS**

Instructions: Type or print clearly. Before completing this form, read the Prior Authorization/Preferred Drug List (PA/PDL) for Non-steroidal Anti-inflammatory Drugs (NSAIDs), Including Cyclo-oxygenase Inhibitors, Completion Instructions, F-11077A. Providers may refer to the Forms page of the ForwardHealth Portal at www.forwardhealth.wi.gov/WIPortal/Content/provider/forms/index.htm.spage for the completion instructions.

Pharmacy providers are required to have a completed Prior Authorization/Preferred Drug List (PA/PDL) for Non-steroidal Anti-inflammatory Drugs (NSAIDs), Including Cyclo-oxygenase Inhibitors form signed by the prescriber before calling the Specialized Transmission Approval Technology-Prior Authorization (STAT-PA) system or submitting a PA request on the Portal or on paper. Providers may call Provider Services at (800) 947-9627 with questions.

SECTION I — MEMBER INFORMATION

1. Name — Member (Last, First, Middle Initial)

2. Member Identification Number

3. Date of Birth — Member

SECTION II — PRESCRIPTION INFORMATION

4. Drug Name

5. Drug Strength

6. Date Prescription Written

7. Directions for Use

8. Name — Prescriber

9. National Provider Identifier (NPI) — Prescriber

10. Address — Prescriber (Street, City, State, ZIP+4 Code)

11. Telephone Number — Prescriber

SECTION III — CLINICAL INFORMATION (Providers are required to complete Section III. For PA requests for cyclo-oxygenase inhibitors, providers are also required to complete Section IIIA.)

12. Diagnosis Code and Description

13. Has the member experienced an unsatisfactory therapeutic response or experienced a clinically significant adverse drug reaction with at least **two** preferred NSAIDs? (The two preferred NSAIDs taken cannot include ibuprofen or naproxen.)

Yes No

If yes, list the preferred NSAIDs and doses, specific details about the unsatisfactory therapeutic responses or clinically significant adverse drug reactions, and the approximate dates the preferred NSAIDs were taken in the space provided.

1. _____
2. _____
3. _____
4. _____

Continued



SECTION IIIA — CLINICAL INFORMATION FOR CYCLO-OXYGENASE INHIBITORS ONLY

- | | | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|-----------------------------|
| 14. Does the member have a history of familial adenomatous polyposis (FAP)? | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| 15. Does the member have medical record documentation of thrombocytopenia or platelet dysfunction? | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| 16. Does the member have medical record documentation of peptic ulcer disease, a history of gastrointestinal (GI) bleeding, or a history of NSAID-induced GI bleeding? | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| 17. Is the member currently taking oral anticoagulation therapy? | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| 18. Has the member been prescribed daily low-dose aspirin for cardioprotection and requires NSAID therapy? | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| 19. Is the member 65 years of age or older? | <input type="checkbox"/> Yes | <input type="checkbox"/> No |

SECTION IV — FOR PHARMACY PROVIDERS USING STAT-PA

- | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|-----------------------------|
| 20. National Drug Code (11 Digits) | 21. Days' Supply Requested (Up to 365 Days) | |
| 22. NPI | | |
| 23. Date of Service (MM/DD/CCYY) (For STAT-PA requests, the date of service may be up to 31 days in the future or up to 14 days in the past.) | | |
| 24. Place of Service | | |
| 25. Assigned PA Number | | |
| 26. Grant Date | 27. Expiration Date | 28. Number of Days Approved |

SECTION V — AUTHORIZED SIGNATURE

- | | |
|----------------------------|-----------------|
| 29. SIGNATURE — Prescriber | 30. Date Signed |
|----------------------------|-----------------|

SECTION VI — ADDITIONAL INFORMATION

31. Include any additional information in the space below. Additional diagnostic and clinical information explaining the need for the product requested may be included here.